Document is current
Any future updates will be listed below
-
Authors
Lehrnbecher, Thomas https://orcid.org/0000-0002-6022-3439
Groll, Andreas H. https://orcid.org/0000-0003-1188-393X
Cesaro, Simone https://orcid.org/0000-0002-8698-9547
Alten, Julia
Attarbaschi, Andishe
Barbaric, Draga
Bodmer, Nicole
Conter, Valentino
Izraeli, Shai https://orcid.org/0000-0002-6938-2540
Mann, Georg
Möricke, Anja
Niggli, Felix
Schrappe, Martin
Stary, Jan
Zapotocka, Ester
Zimmermann, Martin
Elitzur, Sarah https://orcid.org/0000-0002-3495-7578
-
Funding
Funding for this research was provided by:
Deutsche Krebshilfe (108588)
- License Information
-
More Information
Article History
Received: 4 August 2022
Revised: 13 November 2022
Accepted: 15 November 2022
First Online: 12 December 2022
COMPETING INTERESTS
: TL has received grants from Gilead Sciences, has served as consultant to Gilead Sciences, Merck/MSD, Pfizer, Astellas, AstraZeneca and Roche, and served at the speaker´s bureau of Gilead Sciences, Merck/MSD, Astellas, Pfizer and GSK. AHG has received grants from Gilead, Merck, Sharp & Dohme and Pfizer and has served as consultant to Amplyx, Astellas, Basilea, F2G, Gilead. Merck, Sharp & Dohme, Pfizer, Scynexis, and Mundipharma. SC served at the speaker´s bureau of Gilead Sciences and Pfizer. AA has received honoraria for lectures, consultancy or advisory board participation from the following companies: Jazz Pharmaceuticals, Amgen, Novartis, MSD, Jazz Pharmaceuticals, Amgen, Novartis, MSD, and Gilead. He has received compensation for travel expenses from Jazz Pharmaceuticals. MS and/or study group have received research support from SHIRE, JazzPharma, Servier, SigmaTau, Amgen, and Novartis. MS has received honoraria from Servier, Novartis, and JazzPharma.
